Gamco Investors INC. ET AL Sells 1,000 Shares of Electromed, Inc. $ELMD

Gamco Investors INC. ET AL lowered its stake in shares of Electromed, Inc. (NYSE:ELMD) by 0.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 133,000 shares of the company’s stock after selling 1,000 shares during the quarter. Gamco Investors INC. ET AL owned approximately 1.55% of Electromed worth $3,173,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ELMD. Raymond James Financial Inc. bought a new stake in Electromed during the 4th quarter worth about $1,760,000. Barclays PLC boosted its stake in Electromed by 25.0% during the 4th quarter. Barclays PLC now owns 12,529 shares of the company’s stock worth $371,000 after acquiring an additional 2,507 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Electromed by 426.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,055 shares of the company’s stock worth $149,000 after acquiring an additional 4,095 shares during the last quarter. Susquehanna International Group LLP boosted its stake in Electromed by 121.8% during the 4th quarter. Susquehanna International Group LLP now owns 56,726 shares of the company’s stock worth $1,676,000 after acquiring an additional 31,148 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Electromed by 14.1% during the 4th quarter. Northern Trust Corp now owns 65,350 shares of the company’s stock worth $1,931,000 after acquiring an additional 8,086 shares during the last quarter. Institutional investors own 40.82% of the company’s stock.

Electromed Stock Down 1.0%

NYSE ELMD opened at $24.53 on Friday. Electromed, Inc. has a 12-month low of $15.06 and a 12-month high of $35.56. The company has a market capitalization of $205.71 million, a PE ratio of 32.71 and a beta of 0.38. The firm’s 50 day moving average is $19.81 and its 200-day moving average is $22.24.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. B. Riley raised shares of Electromed to a “strong-buy” rating in a research note on Thursday, May 15th. Wall Street Zen lowered shares of Electromed from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 8th. Lake Street Capital began coverage on shares of Electromed in a research note on Wednesday. They issued a “buy” rating and a $36.00 price target on the stock. Roth Capital lifted their price target on shares of Electromed from $29.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Loop Capital set a $36.00 price target on shares of Electromed in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $36.25.

Electromed Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.